NEW YORK (GenomeWeb) – Swedish diagnostic tools developer Immunovia announced today that it has partnered with the Mount Sinai Health System to validate its Immray PanCan-d proteomic blood test for the early detection of pancreatic cancer.
The company said it will launch a three-year clinical study in the US and Europe in the second half of 2016 in order to validate the blood test, and will recruit several health systems and universities to participate. Mount Sinai, the company added, conforms to the basic requirements it has for partners in the study: a broad patient reach, and world renowned clinical expertise in oncology, specifically in pancreatic cancer.
Under the agreement, Mount Sinai will help develop the study's clinical protocols, obtain the required approvals to recruit study subjects, and follow them over the three years. The health system will also deliver the blood samples for analysis and disseminate the results to clinicians and patients.
"Mount Sinai's innovative approach to research and clinical care, scientific excellence, robust clinical research, and beneficial community impact make it the best choice for this collaboration," said Immunovia CEO Mats Grahn in a statement. "We anticipate that upon successful outcome, the data from this prospective clinical trial will be used in regulatory and reimbursement applications of our test."